The Precision Cancer Consortium (PCC) is a collaboration of pharmaceutical companies with a shared vision of enabling access to comprehensive testing for all cancer patients globally. *Shares, likes and comments do not represent the views of our members. The PCC will drive a variety of initiatives aimed at increasing patient access to precision diagnostics using comprehensive genomic testing, including next generation sequencing (NGS). The PCC’s founding members are Bayer, GlaxoSmithKline, Novartis, and Roche. Despite significant treatment advances that target specific molecular alterations in cancer cells, many patients still do not undergo biomarker testing necessary to inform their treatment options. Currently, stakeholders may not be aware of the benefits of comprehensive genomic testing or may not know how to translate results into appropriate patient care. In addition to limited use of precision diagnostics in routine cancer treatment, there are other challenges related to recruiting patients into research studies investigating targeted therapies in biomarker subgroups defined by genomic alterations. PCC’s objective is to support efforts to improve patient access to comprehensive genomic testing in routine care and in clinical trials. The PCC currently has two workstreams. The first workstream aims to remove barriers to access and increase educational awareness on the value of genomic testing for healthcare stakeholders – including patients, healthcare providers, and health care systems. The second workstream focuses on improving efficiencies in genomic biomarker testing in clinical trials. The PCC will not endorse or promote any diagnostic or therapeutic products or services.